HTB

HIV prevention and transmission

Dramatic increase in use of oral TDF/FTC for PrEP in the US – plus a few cautions

Future oral and long-acting formulations for PrEP: pills, films, gels, injections and depots

First data on TAF as PrEP to prevent HIV infection

Long-acting cabotegravir as PrEP protects macaques against IV exposure but will need two-monthly injections

Role for maraviroc as HIV PrEP likely to need dual combinations

Dapivirine PrEP vaginal ring shows only limited PrEP protection against HIV in African women

Canada approves TDF/FTC as PrEP

NHS England pulls proposed timeline for PrEP: perpetuates HIV health crisis in gay men and trans people

UK community campaign calls for NHS England to be accountable for PrEP timeline

European application underway for PrEP indication for tenofovir/FTC

VAT may be payable when importing generic medicines in to the UK

South African Medicines Control Council approves tenofovir/FTC for PrEP

Two cases of HIV transmission on tenofovir DF monotherapy

HIV rates still increasing in gay men: 2015 report

PrEP to be available free in France from January 2016

PrEP efficacy for transgender women: new analysis from iPrEX study

PrEP in a clinical setting: no infections reported in San Francisco cohort

New free self-sampling HIV home testing service launched in England

No transmission of integrase-resistant HIV seen in California cohort

The PrEP experience: IAS 2015 and beyond

i-Base Q&A resources on PrEP: increased use of off-label PrEP in the UK shows need for NHS support and risk to PEP services

Two new UK community PrEP websites

First UK NHS PrEP support service launched at 56 Dean Street, Soho

UK PROUD study published as open access article in The Lancet: PrEP dramatically reduces risk of HIV

Four reasons IAS 2015 will be a milestone HIV conference: a personal view

HPTN 052: no HIV transmissions on effective ART but only limited data on viral failure and drug resistance

Rectal STIs and viral load in HIV positive men on and off ART

Methmephangee – ChemSex vs recreational drug use: a proposed definition for health workers

No HIV transmissions between gay couples when viral load is undetectable: preliminary results from “Opposites Attract” study in Australia, Thailand and Brazil

PrEP reduced HIV risk by at least 86% in PROUD: no transmissions likely from people taking meds

“On demand” PrEP dosing in IPERGAY: 86% reduced risk of HIV, no transmissions with active drug use

Other HIV PrEP studies at CROI 2015: implementation of oral PrEP and problems with tenofovir gel

HIV prevention budget for 2015 slashed by 50%, then rapidly reinstated

Grassroots demand grows for early access to PrEP in the UK

New York announces new policy to dramatically reduce HIV incidence by 2020

UK PROUD study to provide PrEP to all participants earlier than expected: planned follow-up to continue to two years

IPERGAY PrEP study shows early efficacy in protecting gay men from HIV: all participants to switch to active drug

HIV in the UK 2014: Public Health England report on incidence and care

UK PROUD study to provide PrEP earlier than expected: planned follow-up to continue to two years

Antiretroviral studies at ICAAC 2014: darunavir-based FDC with TAF, cobicistat, doravirine, Stribild and gel formulation PrEP

Update on baseline STIs in UK oral PrEP study (PROUD)

HIV reinfection has limited impact on disease progression

Higher ART coverage is associated with lower HIV infection rates in a multi-country analysis

Open label oral PrEP at four doses a week: why zero infections does not equal 100% efficacy

Preventive technologies: antiretroviral and vaccine development

No HIV transmissions with undetectable viral load: interim PARTNER study results show need for longer follow-up

PrEP injections every three months may protect against exposure from anal sex

The little blue pill that can stop HIV: PROUD study enrolling gay men in the UK

Persistence of transmitted drug resistance mutations suggests source partners may be treatment-naive

HIV self testing to become legal in the UK from April 2014

Agreement to develop long-acting rilpivirine as PrEP

Use of ART at baseline by treatment naïve patients in HPTN-052

Partner-dependent immune differences may protect against HIV infection

Bangkok Tenofovir Study: US CDC recommends oral PrEP for injecting drug users – based on 16 fewer infections over 5 years

Preventive technologies, research toward a cure, and immune-based and gene therapies

Monthly injection protects macaques from rectal exposure: results should fast-track human studies for advanced PrEP options

Tenofovir DF ring protects macaques from vaginal exposure

VOICE study reports low adherence as reason for lack of efficacy for PrEP: anal sex common in African heterosexuals

Further studies on how male circumcision may reduce HIV transmission

Minimal risk of sexual HIV transmission for heterosexual couples when the HIV positive partner has an undetectable viral load

UK group describe risk of HIV transmission for people on effective ART as “extremely low”

CDC issues brief on the prevention benefits of HIV treatment

WHO recommendations for prevention and treatment of HIV for sex workers and their clients

Quantifying HIV-1 exposure to illuminate resistance to infection

Immune activation, inflammation and HIV acquisition risk

Post navigation